Loading…
← CockpitCompetitor Analysis › ARWR Arrowhead Pharmaceuticals, Inc.Open in the cockpit ↗

Arrowhead Pharmaceuticals, Inc.ARWRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops RNA-interference (RNAi) drugs that silence disease-causing genes, with a lead cardiometabolic drug and multiple pharma partnerships.

Momentum laggard 8
Mkt cap
$6.09B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$110M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.7%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · USD$43.11
1D+0.3%
1W-12.7%
1M-26.8%
3M-50.7%
6M-44.1%
YTD-35.1%
1Y+7.4%
ATR %6.9%
Beta1.39
52w lowhigh54.9% off high

What Arrowhead Pharmaceuticals does

Develops RNA-interference (RNAi) drugs that silence disease-causing genes, with a lead cardiometabolic drug and multiple pharma partnerships.

Income today comes from partners: upfront and milestone payments, and eventually royalties, from drugmakers that license its RNAi (RNA-interference) technology for specific targets, while it develops its own cardiometabolic drugs. Spending is heavy because it also funds its own trials.

Products and services

  • Plozasiran (cardiometabolic, familial chylomicronemia)
  • Partnered pipeline (GSK, Takeda, Sarepta programs)
  • Pipeline: liver, lung, CNS RNAi targets

Customers

  • Cardiologists/lipid specialists
  • Pharma partners licensing the RNAi platform

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • RNAi drug discovery and development

What could go right

  • Plozasiran commercial launch
  • Milestone/royalty revenue from pharma partnerships

What could go wrong

  • Binary clinical trial risk across the pipeline
  • Dependence on partner milestone payments for near-term revenue

Moat: narrow (IP / patents, process know-how). A proprietary TRiM RNAi delivery platform generates a broad, partnered pipeline across many disease areas.

Headquarters: Pasadena, California, US · Founded: 1989 · Employees: 1,059

Named competitors

Arrowhead Pharmaceuticals at a glance

Size Arrowhead Pharmaceuticals (ARWR) is a United States Health Care company (Biotechnology) with a market value of $6.09B, the 1047th largest of 3,085 United States companies the cockpit tracks. Shares closed at $43.11 on 18 Nov 2026.

Performance Over six months the shares fell 44.1%, against -1.0% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 45.6% over the last twelve months (peer median +16.9%); the operating margin is -156.9% (peer median -11.5%).

Valuation It trades at 14.0× enterprise value to sales against a peer median of 9.8× (7th most expensive of 16).

Credit Arrowhead Pharmaceuticals has 1 bond outstanding ($700M).

Short interest Short interest is 8.2% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 100ARWR 57
Six months, rebased to 100: Arrowhead Pharmaceuticals against the median of its 20 peers (local-currency closes).

Arrowhead Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2026-09-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$451M$451M$829M$3.55M$241M
Revenue growth—-46%+23,258%-99%—
Gross profit$423M$423M$806M-$15.0M$228M
EBITDA-$681M-$681M$122M-$582M-$193M
Net income-$724M-$724M-$1.63M-$599M-$205M
Free cash flow-$284M-$284M$157M-$604M-$331M
Capital expenditure$12.0M$12.0M$22.7M$141M$177M
Total debt$1.40B$1.40B$734M$852M$383M

Quarterly statements and history in the cockpit →

Arrowhead Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%SRRKKODCAIANTHEMIMVT300122AXSMCGONTXG300347COGTDNTHTWSTADPT002252EWTX000661SMMT15301548ARWR6-month return →1-month return →
Up and to the right = strong over both horizons. Arrowhead Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×1,000×1,500×CAIANTHEM300122AXSMCGONTXGDNTHTWST1530ARWRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Arrowhead Pharmaceuticals is the large dot.

Arrowhead Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (ARWR vs ALNY vs IONS vs NOVN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Arrowhead Pharmaceuticals ARWR$6.09B-44%-46%-157%14.0×n/a
Alnylam Pharmaceuticals ALNY$20.0B-50%+56%20%3.9×0.5%
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Wave Life Sciences WVE$546M-55%-35%-321%2.2×n/a
Silence Therapeutics PLC Sponsored ADR SLN$1.23B+244%-98%-11,920%2,161.6×n/a

How Arrowhead Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Arrowhead Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureARWRPeer medianRank in peer set
1-month return-26.8%-0.3%3rd lowest of 21
6-month return-44.1%-1.0%lowest of 21
Distance from 52-week high-54.9%-32.6%3rd lowest of 21
Revenue growth (TTM)-45.6%+16.9%lowest of 15
Operating margin-156.9%-11.5%5th lowest of 16
EV / Sales14.0×9.8×7th most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%8.0×n/an/a
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%1,000.7×n/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%11.3×47.2%+16.6%
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%4.8×25.9%+16.4%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%16.2×n/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%5.4×n/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%9.8×36.9%+19.8%

Arrowhead Pharmaceuticals bonds and credit

Arrowhead Pharmaceuticals has 1 bond outstanding with $700M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Arrowhead Pharmaceuticals's main competitors?
Named competitors: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Novartis (Leqvio) (NOVN.SW), Wave Life Sciences (WVE), Silence Therapeutics (SLN). The cockpit's measured peer set (industry) also includes Scholar Rock (SRRK), Kodiak Sciences (KOD), Caris Life Sciences (CAI), Anthem Biosciences (ANTHEM.NS), Immunovant (IMVT), Chongqing Zhifei Biological Products (300122.SZ).
Is Arrowhead Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 14.0× against a peer median of 9.8×, 7th most expensive of 16 in its peer set.
How has Arrowhead Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -44.1% against -1.0% for the median peer; over one year +7.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.